· Former Member, University of California, Berkeley
Publications (31)
An ErbB3 antibody, MM-121, is active in cancers with ligand-dependent activation.
2010
282
cited
Computational Modeling of ERBB2-Amplified Breast Cancer Identifies Combined ErbB2/3 Blockade as Superior to the Combination of MEK and AKT Inhibitors
2013
106
cited
A Mathematical Model for Neutrophil Gradient Sensing and Polarization
2007
96
cited
Single-cell quantitative HER2 measurement identifies heterogeneity and distinct subgroups within traditionally defined HER2-positive patients.
2013
85
cited
Numerical computation of diffusion on a surface.
2005
54
cited
Calling heads from tails: the role of mathematical modeling in understanding cell polarization.
2009
50
cited
Response to brentuximab vedotin versus physician’s choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis
2021
43
cited
HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B
2016
42
cited
Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma
2022
37
cited
Morphology matters in immune cell chemotaxis: membrane asymmetry affects amplification
2006
24
cited
RESPONSE TO BRENTUXIMAB VEDOTIN BY CD30 EXPRESSION: RESULTS FROM FIVE TRIALS IN PTCL, CTCL, AND B‐CELL LYMPHOMAS
2019
13
cited
Abstract 4633: MM-111, a bispecific HER2 and HER3 antibody, synergistically combines with trastuzumab and paclitaxel in preclinical models of gastric cancer.
2013
11
cited
Model-Based Design of a Decision Tree for Treating HER2+ Cancers Based on Genetic and Protein Biomarkers
2015
5
cited
Abstract LB-410: Phase I dose escalation study of MM-121, a fully human monoclonal antibody to ErbB3, in patients with advanced solid tumors
2011
4
cited
Autonomous Mobile Robot Control Based on White Blood Cell Chemotaxis
2004
3
cited
Preclinical activity of MM-111, a bispecific ErbB2/ErbB3 antibody in previously treated ErbB2-positive gastric and gastroesophageal junction cancer.
2013
3
cited
Abstract 1888: MM-111, a bispecific HER2 and HER3 antibody, inhibits trastuzumab-resistant tumor cell growth
2012
2
cited
Abstract C27: Targeting ErbB3 and EGFR in lung cancer patients: A phase I trial of MM-121 in combination with erlotinib in patients with non-small cell lung cancer (NSCLC).
2011
2
cited
Abstract P1-07-03: Quantification of HER2 expression at the single cell level and HER2 intratumoral heterogeneity of breast cancer tissue samples using automated image analysis
2012
2
cited
Post-treatment biopsies show evidence of cell cycle arrest and immune cell infiltration into tumors of ladiratuzumab vedotin-treated advanced breast cancer patients.
2018
2
cited
Sotabase
Matt Onsum | Researcher Profile | Sotabase | Sotabase